Stoke Therapeutics, Inc.
NASDAQ:STOK
13.27 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 8.78 | 12.405 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 4.729 | 3.535 | 2.23 | 1.926 | 0.45 | 0.214 | 0.113 |
| Gross Profit
| 4.051 | 8.87 | -2.23 | -1.926 | -0.45 | -0.214 | -0.113 |
| Gross Profit Ratio
| 0.461 | 0.715 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 79.762 | 77.837 | 54.168 | 32.197 | 23.764 | 8.371 | 3.598 |
| General & Administrative Expenses
| 41.322 | 38.924 | 31.897 | 20.847 | 11.914 | 4.41 | 1.956 |
| Selling & Marketing Expenses
| -2.26 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 39.062 | 38.924 | 31.897 | 20.847 | 11.914 | 4.41 | 1.956 |
| Other Expenses
| 0.166 | 0.167 | 0.14 | 0.057 | 0.002 | -0.01 | -0.004 |
| Operating Expenses
| 118.824 | 116.761 | 86.065 | 53.044 | 35.678 | 12.781 | 5.554 |
| Operating Income
| -114.773 | -104.356 | -86.065 | -53.044 | -35.678 | -12.781 | -5.554 |
| Operating Income Ratio
| -13.072 | -8.412 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 10.074 | 3.289 | 0.26 | 0.801 | 3.353 | -0.01 | -0.004 |
| Income Before Tax
| -104.699 | -101.067 | -85.805 | -52.243 | -32.325 | -12.521 | -5.558 |
| Income Before Tax Ratio
| -11.925 | -8.147 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 4.561 | -7.957 | -1.094 | -1.632 | -3.801 | 0.26 | 0 |
| Net Income
| -104.699 | -93.11 | -84.711 | -50.611 | -28.524 | -12.521 | -5.558 |
| Net Income Ratio
| -11.925 | -7.506 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.38 | -2.39 | -2.31 | -1.51 | -1.59 | -0.53 | -0.43 |
| EPS Diluted
| -2.38 | -2.39 | -2.31 | -1.51 | -1.59 | -0.53 | -0.43 |
| EBITDA
| -110.044 | -104.356 | -86.065 | -53.044 | -35.678 | -12.567 | -5.441 |
| EBITDA Ratio
| -12.533 | -8.412 | 0 | 0 | 0 | 0 | 0 |